A randomized phase II, open-label trial of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea.
Ayalew Tefferi
No relevant relationships to disclose
Jorge E. Cortes
Research Funding - Sanofi
Andreas Hochhaus
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Merck; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Sanofi
Jean-Jacques Kiladjian
Research Funding - Celgene; Novartis; Shire
Ruben A. Mesa
Research Funding - Sanofi
Animesh Dev Pardanani
No relevant relationships to disclose
Claudia Lebedinsky
Employment or Leadership Position - Sanofi
Frank Neumann
Employment or Leadership Position - Sanofi
Karl Hsu
Employment or Leadership Position - Sanofi
Alessandro M. Vannucchi
Consultant or Advisory Role - Italfarmaco; Novartis
Honoraria - Italfarmaco; Novartis